THURSDAY, Sept. 19, 2024 (HealthDay News) — A specific class of diabetes drug appears to lower people’s risk for dementia and Parkinson’s disease, a new study shows. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, lower blood sugar by prompting the kidneys to filter sugar out of the bloodstream andContinue Reading

WEDNESDAY, Sept. 18, 2024 (HealthDay News) — Cadmium, uranium, cobalt: These and other metals found in the environment can collect in the body and exacerbate heart disease, new research suggests. “Our findings highlight the importance of considering metal exposure as a significant risk factor for atherosclerosis and cardiovascular disease,” saidContinue Reading

WEDNESDAY, Sept. 18, 2024 (HealthDay News) — Therapy dogs can help boost the spirits of health care workers in the same way they brighten the moods of hospital patients, a new study shows.  The furry, four-legged friends reduced emotional exhaustion and job stress among a small group of workers atContinue Reading

TUESDAY, Sept. 17, 2024 (HealthDay News) — Brain training aimed at improving memory can ward off symptoms of Alzheimer’s disease for years, a new study claims. Seniors experienced a slower decline in their memory and thinking abilities after undergoing brain training, compared to others who didn’t get the training, researchersContinue Reading

MONDAY, Sept. 16, 2024 (HealthDay News) — With implications for research around postpartum depression and other health issues, scientists have tracked the changes pregnancy brings to the female brain. These changes weren’t subtle: Big shifts in what’s known as the brain’s “white matter” versus “gray matter” were observed, according toContinue Reading

FRIDAY, Sept. 13, 2024 (HealthDay News) — Over 5 million Americans could benefit if the U.S. Food and Drug Administration approves the “magic mushroom” psychedelic psilocybin as a treatment for depression, researchers estimate. “While our analysis is a crucial first step, we’ve only scratched the surface in understanding the trueContinue Reading

THURSDAY, Sept. 11, 2024 (HealthDay News) — Two monoclonal antibody treatments to slow Alzheimer’s disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It’s thought the drugs curb Alzheimer’s by reducing levels of toxic amyloid protein plaques inContinue Reading